Takeda has joined BaseLaunch, a platform created to launch, fund, and build early biotech ventures developing cutting-edge therapeutics.

Through its investment in BaseLaunch, Takeda gains access to quality life sciences deal flow in central Europe and BaseLaunch’s company-building capabilities, while also providing expertise in biotech innovation and development of medicines. This will further help BaseLaunch develop its portfolio companies, which have collectively raised over $1 billion.

“Our partnership with BaseLaunch strengthens our connection to European biotech innovation,” said Alison Handley, Head of the Center for External Innovation at Takeda. “Further, by joining the investment board, we can help guide company creation and apply Takeda’s expertise in turning science into new therapies. We look forward to participating in BaseLaunch and advancing innovative medicines together.”

“We’re thrilled to welcome Takeda to BaseLaunch. This partnership will significantly benefit our early-stage biotech ventures,” noted Stephan Emmerth, Director of BaseLaunch. “Early-stage funding, coupled with our company-building capabilities and privileged access to our pharma partners, gives our ventures a headstart to further build and grow their businesses.”

Since its inception in 2018, BaseLaunch has supported 27 biotech companies across various modalities and indications, with several of them having entered Phase II clinical trials.

Six of the world’s leading pharmaceutical companies are currently partners of BaseLaunch. In addition to Takeda, these include AbbVie, Roche, Novo Nordisk, Johnson & Johnson and CSL.